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Available online 22 November 2015Objective: To describe abnormalities in large scale functional networks in unmedicated patients with schizophre-
nia and to examine effects of risperidone on networks.
Material and methods: 34 unmedicated patients with schizophrenia and 34 matched healthy controls were en-
rolled in this longitudinal study. We collected resting state functional MRI data with a 3T scanner at baseline
and six weeks after they were started on risperidone. In addition, a group of 19 healthy controls were scanned
twice six weeks apart. Four large scale networks, the dorsal attention network, executive control network, sa-
lience network, and default mode network were identiﬁed with seed based functional connectivity analyses.
Group differences in connectivity, aswell as changes in connectivity over time,were assessed on the group's par-
ticipant level functional connectivity maps.
Results: In unmedicated patients with schizophrenia we found resting state connectivity to be increased in the
dorsal attention network, executive control network, and salience network relative to control participants, but
not the default mode network. Dysconnectivity was attenuated after six weeks of treatment only in the dorsal
attention network. Baseline connectivity in this network was also related to clinical response at six weeks of
treatment with risperidone.
Conclusions: Our results demonstrate abnormalities in large scale functional networks in patients with schizophre-
nia that aremodulated by risperidone only to a certain extent, underscoring the dire need for development of novel
antipsychotic medications that have the ability to alleviate symptoms through attenuation of dysconnectivity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Antipsychotic medication
Default mode network
Dorsal attention network
Executive control network
Salience network1. Introduction
The brain's function is thought to be dependent on coordinated ac-
tivity in complex networks, with the goal of highly efﬁcient information
processing (Achard and Bullmore, 2007). With the advent of functional
magnetic resonance imaging (fMRI), we have been provided opportuni-
ties to gain insights to neural networks in vivo. A growing number ofctuations; BOLD, blood oxygen
Scale; DAN, dorsal attention
using exponentiated lie algebra
ontrol network; FD, framewise
ntrol; KE, cluster extent; MNI,
attery for the Assessment of
.
and Behavioral Neurobiology,
d Ave. South, Birmingham, AL
. This is an open access article understudies suggest schizophrenia to be a disorder of brain network organi-
zation, with symptoms likely related to aberrant communication in net-
works of brain regions (Friston and Frith, 1995).
Resting state fMRI allows examination of intrinsic characteristics of
brain networks, by assessing temporal covariation of low frequency
ﬂuctuations in the blood oxygen level dependent (BOLD) signal across
all voxels in the brain, or functional connectivity (Biswal et al., 1995).
Several cortical resting state networks that are reproducible across dif-
ferent study populations have been identiﬁed. These include the dorsal
attention network (DAN), executive control network (ECN), salience
network, and default mode network (DMN). The DAN and ECN are en-
gaged in higher-order cognitive and attentional control (Seeley et al.,
2007; Dosenbach et al., 2008). The salience network supports integra-
tive processes (Palaniyappan and Liddle, 2012) and the DMN has been
associated with introspection and attention to internal states
(Buckner, 2013; Raichle et al., 2001;Whitﬁeld-Gabrieli and Ford, 2012).
Large scale functional networks appear differentially affected
(Woodward et al., 2011), and increases, decreases, as well as lack ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Resting state fMRI studies examining abnormalities in large-scale networks in schizophrenia.
Study Year Sample
size
(HC/SZ)
Medication status Illness
stage
Field
strength
(Tesla)
Length
of
scan
(min)
Eyes
open/closed
Analysis
type
Results
Dorsal attention network
(Li et al., 2015) 2015 103/121 Medication-naïve/minimally
treated
First
episode
3 6.6 Closed ICA No group differences
(Woodward et al., 2011) 2012 61/42 Medicated Chronic 3 7 Closed Seed based HC N SZ
Executive control network
(Baker et al., 2014) 2014 100/60 Medicated (4 off
medication)
Chronic 3 6.2 Open Seed based HC N SZ
(Chang et al., 2014) 2014 25/25 Medicated (6 off
medication)
Chronic 1.5 6 Closed ICA Mixed increase and decrease in
SZ
(Khadka et al., 2013) 2013 118/70 Medicated Chronic 3 5.25 Open ICA No group differences
(Li et al., 2015) 2015 103/121 Medication-naïve/minimally
treated
First
episode
3 6.6 Closed ICA No group differences
(Littow et al., 2015) 2015 43/43 Medicated Chronic 1.5 8.4 ICA SZ N HC
(Lui et al., 2010b) 2010 34/34 Medication-naïve First
episode
3 6.6 ICA SZ N HC
(Mamah et al., 2013) 2013 33/25 Medicated Chronic 3 13.7 Closed Seed based No group differences
(Manoliu et al., 2014) 2014 20/18 Medicated
(2 off medication)
Chronic 3 10 Closed ICA HC N SZ frontal and parietal
lobe;
SZ N HC temporal and occipital
lobe
(Repovs et al., 2011) 2011 15/25 Medicated Chronic 3 13.7 Closed Seed based No group differences
(Rotarska-Jagiela et al.,
2010)
2010 16/16 Medicated Chronic 3 6.6 Open ICA HC N SZ frontal gyrus,
SZ N HC parietal cortex
(Su et al., 2013) 2013 25/25 Medicated Chronic 3 8.4 Seed based HC N SZ
(Tu et al., 2013) 2013 36/36 Medicated Chronic 3 8.5 Open Seed based HC N SZ
(Wolf et al., 2011; Wolf
et al., 2007)
2011 14/10 Medicated Chronic 3 6 Closed ICA HC N SZ to precuneus,
SZ N HC to frontal lobe
(Woodward et al., 2011) 2012 61/42 Medicated Chronic 3 7 Closed Seed based HC N SZ in frontal regions
(Zhou et al., 2007b) 2007 17/17 Minimally treated First
episode
1.5 6 Closed Seed based Mixed increase and decrease in
SZ
(Zhou et al., 2007a) 2007 18/18 Medicated
(3 off medication)
Recent
onset
1.5 6 Closed Seed based SZ N HC in frontal regions,
HC N SZ in insula and parietal
lobe
Default mode network
(Alonso-Solis et al., 2012) 2012 19/19 Medicated
(2 off medication)
First
episode
3 2.6 Closed Seed based HC N SZ
(Alonso-Solis et al., 2015) 2015 20/33 Medicated Chronic 3 6 Closed Seed based Mixed increase and decrease in
SZ
(Bluhm et al., 2007) 2007 17/17 Medicated
(2 off medication)
Chronic 4 5.5 Closed Seed based HC N SZ
(Camchong et al., 2011) 2011 29/29 Medicated
(2 off medication)
Chronic 3 6 ICA HC N SZ
(Chang et al., 2014) 2014 25/25 Medicated
(6 off medication)
Chronic 1.5 6 Closed ICA SZ N HC
(Guo et al., 2015) 2015 50/49 Medication-naïve First
episode
3 8.3 Closed Seed based SZ N HC
(Jafri et al., 2008) 2008 25/29 Medicated Chronic 3 5 ICA Within network differences
not reported
(He et al., 2013) 2013 113/115 Medication-naïve First
episode
3 6.6 Closed Seed based No group differences
(Khadka et al., 2013) 2013 118/70 Medicated Chronic 3 5.25 Open ICA HC N SZ
(Li et al., 2015) 2015 103/121 Medication-naïve/minimally
treated
First
episode
3 6.6 Closed ICA SZ N HC
(Littow et al., 2015) 2015 43/43 Medicated Chronic 1.5 8.4 ICA SZ N HC
(Lui et al., 2010b) 2010 34/34 Medication-naïve First
episode
3 6.6 ICA HC N SZ
(Mamah et al., 2013) 2013 33/25 Medicated Chronic 3 13.7 Closed Seed based No group differences
(Mannell et al., 2010) 2010 16/16 Medicated Chronic 1.5 8 ICA and seed
based
SZ N HC in posterior regions,
HC N SZ in frontal regions
(Manoliu et al., 2014) 2014 20/18 Medicated
(2 off medication)
Chronic 3 10 Closed ICA HC N SZ
(Meda et al., 2012) 2012 118/70 Medicated Chronic 3 5.25 Open ICA Within network differences
not reported
(Meda et al., 2012; Meda
et al., 2014)
2014 324/296 Medicated
(11 off medication)
Chronic 3 5 Open ICA HC N SZ
(Mingoia et al., 2012) 2012 25/25 Medicated Chronic 3 9 Closed ICA Mixed increase and decrease in
SZ
(Ongur et al., 2010) 2010 15/14 Medicated Chronic 3 10 Open ICA HC N SZ in the ACC;
SZ N HC in basal ganglia
(Orliac et al., 2013) 2013 26/26 Medicated Chronic 3 8 Closed ICA HC N SZ
(Repovs et al., 2011) 2011 15/25 Medicated Chronic 3 13.7 Closed Seed based No group differences
(Rotarska-Jagiela et al., 2010 16/16 Medicated Chronic 3 6.6 Open ICA HC N SZ
(continued on next page)
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Table 1 (continued)
Study Year Sample
size
(HC/SZ)
Medication status Illness
stage
Field
strength
(Tesla)
Length
of
scan
(min)
Eyes
open/closed
Analysis
type
Results
2010)
(Skudlarski et al., 2010) 2010 27/27 Medicated Chronic 3 5.25 Seed based SZ N HC
(Swanson et al., 2011) 2011 28/28 Medicated Chronic 3 5 ICA Differences in network
laterality
(Tang et al., 2013) 2013 32/32 Medicated
(6 off medication)
Early
onset
1.5 6 Closed ICA SZ N HC
(Wang et al., 2015) 2015 53/55 Medicated
(34 drug naïve)
First
episode
3 8 Closed ICA SZ N HC
(Whitﬁeld-Gabrieli et al.,
2009)
2009 13/13 Medicated
(3 off medication)
Chronic 1.5 Seed based SZ N HC
(Wolf et al., 2007) 2011 14/10 Medicated Chronic 3 6 Closed ICA No group differences
(Woodward et al., 2011) 2012 61/42 Medicated Chronic 3 7 Closed Seed based SZ N HC
(Zhou et al., 2007a) 2007 18/18 Medicated
(3 off medication)
Recent
onset
1.5 6 Closed Seed based SZ N HC
Salience network
(Li et al., 2015) 2015 103/121 Medication-naïve/minimally
treated
First
episode
3 6.6 Closed ICA No group differences
(Mamah et al., 2013) 2013 33/25 Medicated Chronic 3 13.7 Closed Seed based No group differences
(Manoliu et al., 2014) 2014 20/18 Medicated
(2 off medication)
Chronic 3 10 Closed ICA HC N SZ in insula;
SZ N HC in frontal regions
(Moran et al., 2013) 2013 44/44 Medicated Chronic 3 5 Open Seed based HC N SZ
(Orliac et al., 2013) 2013 26/26 Medicated Chronic 3 8 Closed ICA HC N SZ
(Palaniyappan et al., 2013) 2013 35/38 Medicated
(2 off medication)
Chronic 3 10 Open Seed based Mixed increase and decrease in
SZ
(Pu et al., 2012) 2012 90/90 Medicated
(16 drug naïve)
Recent
onset
1.5 6 Closed Seed based HC N SZ
(Woodward et al., 2011) 2012 61/42 Medicated Chronic 3 7 Closed Seed based No group differences
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2012; Williamson and Allman, 2012; Mamah et al., 2013; Fornito
et al., 2011; Whitﬁeld-Gabrieli et al., 2009; Ongur et al., 2010; Repovs
et al., 2011), for a summary of studies examining large scale network ab-
normalities at rest, please see Table 1. The DMN is the most widely in-
vestigated large scale network in patients with schizophrenia. Some
studies suggest hyperconnectivity of the DMN (Whitﬁeld-Gabrieli
et al., 2009; Zhou et al., 2007a; Guo et al., 2015), while others ﬁnd a
mix of hyperconnectivity in posterior regions and hypoconnectivity in
anterior regions of the network (Ongur et al., 2010; Mannell et al.,
2010; Camchong et al., 2011). An activation likelihood meta-analysis
of DMN resting state studies in predominantly medicated patients
with schizophrenia discovered hypoconnectivity in the posterior cingu-
late cortex, hippocampus, and medial prefrontal cortex, as well as
hyperconnectivity in the lingual gyrus (Kuhn and Gallinat, 2013). Re-
sults are also variable in other large scale networks in schizophrenia.
While one study reported no functional abnormalities in the ECN in
antipsychotic-naïve, ﬁrst episode schizophrenia patients (Lui et al.,
2009), ECN connectivity has been found reduced in the dorsolateral pre-
frontal cortex (Woodward et al., 2011; Zhou et al., 2007a), possibly
spanning to the parietal aspects of the network (Baker et al., 2014) in
medicated patients. Salience network alterations in schizophrenia are
inconsistent as well with reductions in connectivity in the anterior cin-
gulate cortex and insula reported in the early stage of the illness (Pu
et al., 2012), but increased anterior cingulate together with decreased
insula connectivity described in the chronic stage (Woodward et al.,
2011; Manoliu et al., 2014). Others reported intact within salience net-
work connectivity (Woodward et al., 2011; Mamah et al., 2013). Data is
limited for the DAN in schizophrenia, but connectivity in this network
may also be aberrant (Woodward et al., 2011). High variability between
studies may be due to several factors, including sample size, image
acquisition and analyses methods, data quality, and clinical
heterogeneity.
It is likely that differences in the patient population such as medica-
tion management may account for a portion of the variability in ﬁnd-
ings. However, few attempts have been made to characterize largescale functional networks at rest in unmedicated patients with schizo-
phrenia and to examine systems-level effects of antipsychotic medica-
tion on these measures, despite evidence suggesting that functional
network architecture is sensitive to neuromodulation (Cole et al.,
2013a; van de Ven et al., 2013; Schaefer et al., 2014). Dopamine
targeting agents such as L-dopa, methylphenidate, and haloperidol
have been shown to affect functional connectivity in healthy subjects
(Cole et al., 2013a; Sripada et al., 2013; Cole et al., 2013b). In patients
with schizophrenia, our group has reported that abnormally low ventral
tegmental area to thalamus connectivity observed in unmedicated pa-
tients was restored to more normal patterns after one week of treat-
ment with risperidone (Hadley et al., 2014). Sarpal and colleagues
reported increases in connectivity between striatal seed regions and
the thalamus in a group of ﬁrst episode psychosis patients after twelve
weeks of treatment with risperidone or aripiprazole and also reported
changes in fronto-limbic to striatal connectivity as a function of good
clinical response (Sarpal et al., 2015). Olanzapine has been reported to
increase functional connectivity in DMN connectivity with the ventro-
medial prefrontal cortex, but not posterior regions of the DMN between
weeks four and eight of treatment (Sambataro et al., 2010). Examining
amplitudes of low frequency ﬂuctuations (ALFF), another measure in
functional connectivity, another group showed increased ALFF in pre-
frontal, parietal and temporal areas after six weeks of treatment with
various second generation antipsychotic medications (Lui et al., 2010a).
The purpose of this study was to better characterize systems-level
effects of risperidone, a commonly prescribed second generation anti-
psychotic medication, on large scale resting state networks in schizo-
phrenia. We obtained resting state scans before medication was
initiated (in unmedicated subjects) and after six weeks of treatment
to investigate antipsychotic effects on four large scale networks, the
DAN, the ECN, the salience network, and theDMN. Based on the existing
literature, we hypothesized large scale functional networks to be differ-
entially affected in unmedicated patients and that network integrity
would be, at least partially, restored after six weeks of antipsychotic
treatment. We also conducted exploratory analyses to investigate asso-
ciations between connectivity and clinical variables.
Table 2
Demographics and clinical measures.a
SZ (n = 34) HC (n = 34) t/X2 p
value
Gender (% male) 67.6 67.6 0.000 1.0
Age 32.38
(10.43)
32.00 (9.02) −.382 .87
Parental occupationb 7.26 (6.39) 6.21 (4.35) −0.80 .43
Smoking status (% smokers) 76.5 64.7 1.133 .42
Smoking (packs per day) 0.59 (0.53) 0.65 (0.60) 0.447 .66
Diagnosis
Schizophrenia 31
Schizoaffective disorder 3
Illness characteristics
Illness duration (years) 9.59 (9.94)
First episode 12
Prior antipsychotic treatment
Antipsychotic naive 17
Antipsychotic free interval
(months)
23.08
(44.41)
BPRSc
Total
Baseline 48.29 (9.38)
Week 6d 30.57 (8.47)
Positive
Baseline 9.53 (3.04)
Week 6d 4.86 (2.38)
Negative
Baseline 6.79 (2.51)
Week 6d 5.39 (2.42)
RBANSe
Total index 70.21
(13.76)
94.47
(13.99)
6.773 b.01
Immediate memory 74.68
(16.86)
96.53
(12.78)
4.962 b.01
Visuospatial 71.41
(15.48)
89.18
(19.15)
5.549 b.01
Language 84.71
(12.85)
96.68
(13.92)
3.663 b.01
Attention span 79.03
(20.32)
100.82
(18.92)
5.001 b.01
Delayed memory 72.53
(19.10)
93.53
(11.72)
5.348 b.01
SZ, schizophrenia; HC, healthy control.
a Mean (SD) unless indicated otherwise.
b Ranks determined from Diagnostic Interview for Genetic Studies (1–18 scale); higher
rank (lower numerical value) corresponds to higher socioeconomic status.
c Brief Psychiatric Rating Scale (1–7 scale); positive (conceptual disorganization, hal-
lucinatory behavior, and unusual thought content); negative (emotional withdrawal, mo-
tor retardation, and blunted affect).
d n = 28.
e Repeatable Battery for the Assessment of Neuropsychological Status.
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Unmedicated patients with schizophrenia or schizoaffective disor-
der (SZ) were recruited from various outpatient clinics, the inpatient
unit and emergency room at the University of Alabama at Birmingham
(UAB). Healthy controls (HC) matched on age, sex, parental occupation
and smoking status were recruited by advertisements in ﬂyers and the
university's newspaper. Approval for this investigator-initiated study
was obtained by the UAB Institutional Review Board. Written informed
consent to participate in the study was obtained after subjects were
deemed competent to provide consent (Carpenter et al., 2000).
Diagnoses were established by review of medical records and con-
sensus of two clinicians and then conﬁrmed with the Diagnostic Inter-
view for Genetic Studies (Nurnberger et al., 1994). All SZ were off
antipsychotic medication for at least ten days and agreed to treatment;
medication was not discontinued to meet this criterion. Subjects were
excluded if they had a major medical or neurological condition, history
of head traumawith loss of consciousness,met criteria for amoderate or
severe substance use disorder other than nicotine use disorder withinsix months of imaging, were prescribed medications known to affect
brain function, were pregnant or breastfeeding, or had any MRI contra-
indications. A personal or family history in a ﬁrst-degree relative of an
Axis I disorder was an exclusion criterion for HC.
Subjects who were either medication naïve or had been off antipsy-
chotic medications were enrolled in a six week trial with risperidone
using a ﬂexible dosing regimen. Medication was managed by two psy-
chiatrists (ACL and NVK), and dose determinations were based on ther-
apeutic and side effects. Starting doses were 1–3mg; titrationwas done
in 1–2mg increments. Compliancewasmonitored by pill counts at each
visit. Concomitant antidepressant or mood stabilizing medication was
allowed to be used as indicated. Resting state scans were obtained
prior to treatment (off medication) and after six weeks of treatment
with risperidone.
Of the 68 subjects enrolled, oneHCwas excluded frombaseline anal-
ysis because of poor scan quality. In the SZ group 6 subjects dropped out
of the study prior to the second scan. Additionally, no resting state data
was available for 6 subjects at week 6 (resting state scans not obtained
for 5 subjects, poor scan quality in 1 subject), leaving data for 34 SZ at
baseline and 22 SZ at week 6 in the ﬁnal analysis. Additionally, we
scanned a group of 19 HC twice six weeks apart to give us the ability
to assess connectivity changes over time. Resting state data from some
subjects have been included in earlier reports (Hadley et al., 2014;
Kraguljac et al., 2014).
2.1. Clinical variables
The Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS) was used to characterize general cognitive function
(Randolph et al., 1998). The Brief Psychiatric Rating Scale (BPRS) was
used for weekly assessments of symptom severity (Overall and
Gorham, 1962).
2.2. MRI acquisition
All imaging was performed on a 3T head-only scanner (Magnetom
Allegra, Siemens Medical Solutions), equipped with a circularly polar-
ized transmit/receive head coil. Resting state fMRI scans were acquired
during a ﬁve-minute gradient recalled echo-planar imaging sequence
(repetition time/echo time [TR/TE] = 2000/30 msec, ﬂip angle = 70°,
ﬁeld of view = 192 × 192 mm2, 64 × 64 matrix, 6-mm slice thickness,
1-mm gap, 30 axial slices, 150 acquisitions). During the scan, subjects
were instructed to keep their eyes open and stare passively ahead.
High-resolution structural scans were acquired using the three-
dimensional T1-weighted magnetization prepared rapid acquisition
gradient-echo sequence (TR/TE/inversion time [TI] = 2300/3.93/
1100 msec, ﬂip angle = 12°, 256 × 256 matrix, 1 mm isotropic voxels).
All MRI scans were reviewed for abnormalities by a neuroradiologist.
2.3. Functional connectivity analysis
Using the statistical parametric mapping package SPM8 (Wellcome
Trust Centre for Neuroimaging, London, UK), resting state data were
slice timing corrected, realigned using rigid-body motion transforms,
co-registered to the high-resolution structural scan, normalized to
1.5 mm3 Montreal Neurologic Institute (MNI) space, and spatially
smoothed employing the diffeomorphic anatomical registration using
exponentiated lie algebra algorithm (DARTEL) with a 6-mm at full-
width half-maximum three-dimensional Gaussian kernel (Asami et al.,
2012).
To remove physiological noise from data, a nuisance regression was
ﬁrst conducted using the six motion parameters identiﬁed during the
realignment step and their ﬁrst derivatives as regressors. Next, a step-
wise data scrubbing procedure was followed to reduce the effects of
time points severely contaminated by motion (Power et al., 2012).
Framewise displacements from each time point, i, to the next (FDi)
Fig. 1. Resting state networks in healthy controls (HC; n = 33; left column) and unmedicated patients with schizophrenia (SZ baseline; n = 34; right column). Statistical maps are sig-
niﬁcant at PFDR b .001. Results are projected on BrainNet Viewer surfacemap,medium view. Abbreviations: DAN: dorsal attention network; ECN: executive control network; DMN: default
mode network; L: left; R: right.
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dius r = 50 mm, approximately the mean distance from the center of
MNI space to the cortex, was used to convert angle rotations (radians)
to displacements (mm). Timepointswith FDi N 0.5mmwere considered
to be severely contaminated with motion or other artifact. These con-
taminated time points were ﬁrst interpolated prior to bandpass ﬁltering
of the data (0.009 b f b 0.08 Hz) (Carp, 2013), and then excluded fromsubsequent analyses (Power et al., 2013). To assess motion effects on
connectivity data, we calculated mean absolute framewise displace-
ment of the brain from one timeframe to the next for each subject.
There were no signiﬁcant differences in mean absolute framewise dis-
placement between HC and unmedicated SZ, or between time points
in SZ (HC: 0.17 +/− 0.23 mm; SZ baseline: 0.23 mm +/− 0.23 mm;
SZ week 1: 0.17 +/− 0.12 mm; SZ week 6: 0.23 mm +/− 0.23 mm;
151N.V. Kraguljac et al. / NeuroImage: Clinical 10 (2016) 146–158all p N .05), however, more timepoints were scrubbed in SZ than HC
(t=−2.781; p b .01). Following data scrubbing, a principle component
analysis was used to extract the components of white matter and cere-
bral spinal ﬂuid necessary to explain 90% of signal variance from those
regions. These extracted components were used as regressors in a sec-
ond nuisance regression (Behzadi et al., 2007).
Spherical seeds with 6 mm radius were placed at the following MNI
coordinates to deﬁne resting state networks as described in previous
studies (Seeley et al., 2007; Woodward et al., 2011; Vincent et al.,
2006; Achard and Bullmore, 2007) −25/−53/52 and 25/−57/52
(intraparietal sulcus and superior parietal lobe) for the DAN, (Friston
and Frith, 1995)−42/34/20 and 44/36/20 (left and right dorsolateral
prefrontal cortex) for the ECN, (Biswal et al., 1995)−32/26/−14 and
38/22/−10 (left and right fronto-insular cortex) for the salience net-
work, and (Seeley et al., 2007) 1/−55/17 (posterior cingulate cortex)
for the DMN.
The ﬁrst eigenvariate of the BOLD time series fromeach seedwas ex-
tracted and correlated to the time series of all other voxels in the brain
to produce functional connectivity maps (units of Pearson's r correla-
tion). For networks with bilateral seeds, these were averaged to form
a single functional connectivity map of each network for each subject.Fig. 2. Resting state connectivity abnormalities in unmedicated patients with schizophrenia (n
increased connectivity in unmedicated patients compared to controls. No clusters with decre
maps are signiﬁcant at PFDR b .05. Clusters are overlaid on the Xjview single subject T1 templat
x and z coordinates in MNI convention. Color bar indicates t values. Abbreviations: DAN: dorsaMaps were converted to normally distributed values using Fisher's r-
to-Z transform.
Group-level functional connectivity maps were obtained by
performing one-sample t-tests on each group's participant-level func-
tional connectivity maps. Group differences in functional connectivity,
as well as differences between medication-naïve and previously medi-
cated patients, were assessed using two-sample t-tests on the groups'
participant-level functional network connectivitymaps. To restrict anal-
yses to include only those brain regions that were recruited by at least
one of the groups, we created thresholded t-maps (PFDR b .01) combin-
ing groups. We computed these by creating one-sample t-tests for each
resting state network and both diagnostic groups (both points in SZ)
that were binarized and combined, thus producing masks of the com-
bined connected areas. These masks were used in between group com-
parisons and comparisons across time within each large scale network.
All analyseswere corrected formultiple comparisons using the false dis-
covery rate and are reported at PFDR b 0.001 for main effects within
group and at PFDR b 0.05 for group differences and change over time.
To assess connectivity changes over time in healthy controls we im-
plemented two statistical tests. First, we used paired-sample t-tests on
the participant-level functional network connectivity maps for each= 34) compared to healthy controls (n = 33). Clusters indicate areas with signiﬁcantly
ased connectivity in unmedicated patients compared to controls are present. Statistical
e, left columns show a sagittal slice, all others are axial. Numbers below the slices indicate
l attention network; ECN: executive control network.
Table 3
Increased functional connectivity in unmedicated patients with schizophrenia compared to healthy controls.
Brain regions Voxels in cluster Hem. Voxels in region Peak coordinatesa Peak t PFDRb
X Y Z
Dorsal attention network
Cluster 1 2971 24 −54 51 3.891
Superior parietal gyrus B 468
Inferior parietal gyrus B 228
Cuneus/precuneus B 665
Superior and middle occipital gyrus L 534
Cluster 2 2234 15 −70.5 31.5 3.673
Middle temporal gyrus R 119
Angular gyrus R 56
Superior parietal gyrus R 66
Cuneus/precuneus R 741
Superior and middle occipital gyrus R 701
Calcarine sulcus R 174
Executive control network
Cluster 1 1450 −30 52.5 13.5 4.369
Superior frontal gyrus L 141
Middle frontal gyrus L 1195
Inferior frontal gyrus L 109
Cluster 2 1344 −9 31.5 30 3.779
Superior medial frontal gyrus B 364
Supplemental motor area B 77
Anterior cingulate cortex B 269
Middle cingulate cortex L 734
Salience network
Cluster 2615 34.5 −13.5 12 4.613
Rolandic operculum R 118
Pallidum/putamen B 765
Caudate B 580
Insula R 253
Amygdala R 32
Default mode network
No clusters
Abbreviations: Hem., hemisphere; L, left; R, right.
a Reported in Montreal Neurologic Institute coordinates (X, Y, and Z).
b All comparisons were FDR-corrected (PFDR ≤ 0.05).
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calculated intra-subject reliability at the network level implemented
in the ICC toolbox (http://brainmap.co.uk). Intra voxel intra-class corre-
lation coefﬁcients (ICC) were calculated for each subject using the con-
trast values of the voxels within the networks. The median ICC and
standard errors were obtained from a bootstrapped ICC distribution
with 1000 re-samples per subject (Caceres et al., 2009).
In an exploratory fashion, we also examined the relationships be-
tween connectivity and clinical variables. To assess the relationship be-
tween functional connectivity of each network and symptom burden at
baseline in patients with schizophrenia, we used a general linear model
that included BPRS total scores and one that included RBANS total
scores. To restrict analyses to each network, above described masks
were used in the general linearmodel. Treatment response was deﬁned
as (BPRS positive score at baseline− BPRS positive score at 6 weeks) /
BPRS positive score at baseline. We were able to assess treatment re-
sponse for 28 subjects at week 6, and carried forward week 5 data
from two subjects, totaling of 30 subjects with treatment response
scores.
3. Results
3.1. Demographics and behavioral results
Of the 34 SZ subjects, 22 were chronically ill and 12 experienced
their ﬁrst episode. 17 SZwere antipsychotic naïve (ﬁve had not received
prior treatment despite a prolonged period since illness onset), and 17
have had prior exposure to antipsychotic medication. Average dose of
risperidone at endpoint was 4.36 +/− 1.45 mg. Twelve subjects were
concomitantly treated with benztropine, two with trazodone, one
each was prescribed mirtazapine, amitriptyline, and valproic acid.There were no signiﬁcant differences between HC and SZ in age, sex,
parental socioeconomic status, or smoking status (Table 2). As expected,
SZ scored signiﬁcantly lower on the RBANS compared to HC. In SZ, BPRS
total scores decreased from 48.29 +/− 9.38 at baseline to 30.57 +/−
8.47 after six weeks of treatment.
3.2. Imaging results
3.2.1. Functional connectivity in HC and unmedicated SZ
In HC, analyses revealed functional network architecture of all four
large scale networks consistent with prior reports (Fig. 1); connectivity
patterns at the group level did not signiﬁcantly change between base-
line and week six in any of the networks in the 19 HC scanned twice.
Median intra-voxel ICC in HC between the two scans was 0.44 +/−
0.03 for the DAN, 0.35 +/− 0.07 for the ECN, 0.38 +/− 0.08 for the sa-
lience network, and 0.33 +/− 0.07 for the DMN.
In unmedicated SZ, we found increased functional connectivity in
the DAN, ECN, and salience networks, but not the DMNwhen compared
to HC (Fig. 2). There were no areas of decreased connectivity in any of
the resting state networks. Connectivity patterns did not signiﬁcantly
differ between the 17 medication naïve and 17 previously medicated
SZ in any network. DAN connectivity was increased in the angular
gyrus, middle temporal gyrus, superior and inferior parietal gyri,
cuneus/precuneus, superior and middle occipital gyrus, and calcarine
sulcus. In the ECN, we noted elevated connectivity in the superior fron-
tal, middle frontal, and inferior frontal gyri, supplemental motor cortex,
as well as anterior and middle cingulate cortices. Connectivity was also
increased in the rolandic operculum, insula, basal ganglia and amygdala
in the salience network (Table 3). Using more stringent corrections we
found that ECN connectivity to the inferior frontal gyrus was increased
(t = 4.37, PFDR b .01, kE [cluster extent, number of voxels] = 493, MNI
Fig. 3. Dorsal attention network connectivity, effects of risperidone and treatment response. Top row: Clusters indicate regions where connectivity strength in unmedicated patients with
schizophrenia is related to clinical response after six weeks of treatment with risperidone (n = 30). Bottom row: Clusters indicate regions showing changes in functional connectivity in
patients with schizophrenia between baseline and week 6 (n= 22). Statistical maps are signiﬁcant at PFDR b .05. Clusters were overlaid on the Xjview single subject T1 template, left col-
umns show a sagittal slice, all others are axial. Numbers below the slices indicate x and z coordinates in MNI convention. Color bar indicated t values.
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creased connectivity in the DAN or salience networks. To better under-
stand the increase in connectivity (and because the number of voxels
functionally connected to the seed region was 11% higher in the DAN
and 17% higher in the ECN, salience network, and DMN in unmedicated
SZ compared to HC),we conducted a post-hoc analysis limiting analyses
of connectivity differences between HC and unmedicated SZ only to
areas included in HC network (i.e. all voxels that functionally connected
to the seed in HC). We found no abnormalities in any of the networks
(all PFDR N .05) or differences in mean signal amplitude (DAN:
t = −0.102; p = .91; ECN: t = −0.293; p = .77; salience network:
t = 1.357; p = .18; DMN: t = 0.544; p = .59), suggesting that the in-
crease in functional connectivity seen in SZ may be related to topo-
graphical expansion of large scale networks rather than abnormally
increased connectivity within areas that are typically part of the
networks.
3.2.2. Relationship between abnormalities in large scale networks and
symptom burden
Exploratory analyses to investigate associations between connectiv-
ity and clinical variables were also conducted. We found that higherBPRS total scores in unmedicated SZ were related to higher DMN func-
tional connectivity strength in one cluster in the bilateral precuneus/
posterior cingulate cortex (t = 3.86, PFDR b .05, kE = 2029, MNI coordi-
nates: x = 0, y = −72, z = 39; Fig. 3), but this association was not
unique to symptom dimension. Lower RBANS scores were associated
with higher salience network connectivity strength in one cluster in
the right insula and inferior frontal cortex (t = 5.61, PFDR b .05, kE =
2665, MNI coordinates: x=34, y=30, z=−4; Fig. 3), no relationship
between RBANS scores and salience network connectivity strength was
found inHC. Greater baselineDANconnectivity in two clusters spanning
the cuneus/precuneus, superior and inferior parietal lobes, lingual
gyrus, middle occipital lobe, and calcarine sulcus was associated with
eventual clinical response at week six (Cluster 1: t = 4.91, PFDR b .05,
kE = 1677, MNI coordinates: x = 8, y =−34, z = 51; Cluster 2: t =
4.42, PFDR b .05, kE = 2701, MNI coordinates: x = −36, y = −84,
z= 20; Fig. 4).
3.2.3. Change in functional connectivity over time with risperidone
treatment
We observed resting state functional connectivity changes after six
weeks of treatment with risperidone only in the DAN, but none of the
Fig. 4.Relationship between resting state functional connectivity and clinical variables in patients with schizophrenia (n=34). Left: Clusters indicate regionswhere connectivity strength
within the network where is correlated with symptom severity. Statistical maps are signiﬁcant at PFDR b .05. Clusters are overlaid on the Xjview single subject T1 template, left column
shows a sagittal slice, middle column shows an axial slice. Numbers below the slices indicate x and z coordinates in MNI convention. Color bar indicates t values. Right: Correlations be-
tween baseline functional connectivity strength and symptom severity. Abbreviations: DMN: default mode network; BPRS: Brief Psychiatric Rating Scale; RBANS: Repeatable Battery for
the Assessment of Neuropsychological Status.
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overall decrease in connectivity was seen in the lingual gyrus, fusiform
gyrus, precuneus, calcarine sulcus and cerebellum. No areas within the
DAN showed increased connectivity compared to baseline (Table 4,
Fig. 4). Using more stringent corrections (PFDR b .01) we observed no
change in connectivity over time in the DAN. Median intra-voxel ICC
in SZ between the two scans was 0.48 +/− 0.06 for the DAN,Table 4
Change in dorsal attention network functional connectivity over six weeks of treatment
with risperidone.
Brain regions Voxels
in
cluster
Hem. Voxels
in
region
Peak coordinatesa Peak
t
PFDR
b
X Y Z
Baseline N week 6
Cluster 1454 −6 −64.5 −9 4.217
Lingual gyrus B 754
Fusiform
gyrus
B 132
Precuneus B 47
Calcarine
sulcus
B 22
Cerebellum L 380
Abbreviations: Hem., hemisphere; L, left; R, right.
a Reported in Montreal Neurologic Institute coordinates (X, Y, and Z).
b All comparisons were FDR-corrected (PFDR ≤ 0.05).0.38 +/− 0.03 for the ECN, 0.36 +/− 0.06 for the salience network,
and 0.70 +/− 0.04 for the DMN.
4. Discussion
To our knowledge, this is the ﬁrst longitudinal study characterizing
four large-scale brain networks in unmedicated patients with schizo-
phrenia and the effects of risperidone on resting state functional con-
nectivity. We report functional architecture of each network in
healthy controls that is principally consistent with the existing litera-
ture and show increased resting state connectivity in the DAN, ECN,
and salience networks, but not DMN, in unmedicated patients; abnor-
malities did not differ between medication-naïve subjects and those
with prior exposure to antipsychotic medications. Additionally, we
demonstrate attenuation of dysconnectivity in the DAN after six
weeks of treatment with risperidone and a possible link between base-
line DAN connectivity strength and eventual clinical response.
Ourﬁndings are in agreementwith the concept of schizophrenia as a
disorder of brain network organization and a prior report of resting
state networks being differentially affected in schizophrenia
(Woodward et al., 2011). A number of studies suggest widespread ab-
normalities in large scale networks in schizophrenia (Khadka et al.,
2013; Meda et al., 2012; Shefﬁeld et al., 2015; Orliac et al., 2013;
Moran et al., 2013;Wolf et al., 2011), but disturbances vary by network,
and neither directionality (increase or decrease) nor spatial patterns of
dysconnectivity appear consistent (Williamson and Allman, 2012; Yu
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decreased DMN connectivity and increased ECN connectivity to the left
parietal cortex in patients with schizophrenia compared to healthy con-
trols, but observed no group differences in other large scale networks
(Rotarska-Jagiela et al., 2010). In a large group of medication-naïve
ﬁrst episode schizophrenia patients, resting state ALLFs were found to
be decreased in areas of the DMN and ECN (Ren et al., 2013). Examining
topological properties of functional network connectivity using graph
metrics, another study reports abnormalities in areas of the brain that
are typically conceptualized as part of the DMN, ECN, and motor net-
work in medicated patients with schizophrenia compared to healthy
controls (Yu et al., 2011).We report an increase in resting state connec-
tivity in networks that typically show activation in response to goal di-
rected tasks. The negative correlation between salience network
connectivity strength and RBANS scores is consistent with prior reports
linking aberrant connectivity in this network with information process-
ing deﬁcits in schizophrenia (White et al., 2010). Similar to Baker et al.
who examined resting state ECN integrity across the psychosis spec-
trum, we did not see a relationship between connectivity disruption
and clinical variables (Baker et al., 2014). Somewhat surprisingly, we
did not observe dysconnectivity in the DMN, a network that is often re-
ported abnormal inmedicatedpatientswith schizophrenia (Williamson
and Allman, 2012), and possibly even in unaffected relatives of patients
with schizophrenia (Meda et al., 2014; Chang et al., 2014) [but also see
(Wolf et al., 2011), which did not ﬁnd aberrant DMN connectivity]. To
our knowledge, all resting state studies examining the DMN to date
have enrolled medicated subjects, which may explain discrepancies in
ﬁndings.
Our ﬁndings suggest that increased network connectivity seen in
unmedicated patients with schizophrenia may be related to topograph-
ical expansion of networks. Examining the spatial extent of resting state
networks, wider connectivity in the ECN and greater spatial dispersion
of the DMN in schizophrenia compared to healthy controls have been
reported (Woodward et al., 2011; Littow et al., 2015). However, the cel-
lular levelmechanisms of aberrant resting state connectivity remain un-
clear. Postmortem studies report abnormalities in both excitatory and
inhibitory neuronal components, such as reduced NMDA-receptor ex-
pression (Beneyto et al., 2007), disrupted glutamate transport protein
complex integrity (Shan et al., 2014), reductions in parvalbumin con-
taining interneurons (Lewis et al., 2012), and lower glutamic-acid-
decarboxylase levels, the rate-limiting enzyme of GABA production
(Akbarian andHuang, 2006). Disruption in the excitation/inhibition bal-
ance may lead to increase of excitability in cortical microcircuitry, im-
pact connectivity in large-scale networks, and result in behavioral
abnormalities (Krystal et al., 2003; Uhlhaas, 2013; Deco et al., 2014).
Consistent with this, administration of ketamine, a NMDA receptor an-
tagonist, has been found to globally increase functional connectivity
during rest (Driesen et al., 2013). In a complementary experiment, ex-
amining large scale networks during a working memory task, Anticevic
and colleagues demonstrated a disruption in the reciprocal relationship
between networks and interpreted this as evidence of cortical disinhibi-
tion secondary to NMDA receptor hypofunction (Anticevic et al., 2012).
In light of these ﬁndings, it is tempting to speculate that the increase in
connectivity we see in schizophrenia could be secondary to an aberrant
excitation/inhibition balance.
Our ﬁndings extend the existing literature by showing that risperi-
done, a commonly prescribed antipsychoticmedication,may affect rest-
ing state functional connectivity in patients with schizophrenia. Thus
far, the majority of studies have considered antipsychotic medications
as confounding variable rather thanmodulating factor. Only few studies
have explicitly investigated systems-level effects of antipsychotic med-
ications on resting state connectivity. Lui et al. examined connectivity in
medication-naïve, ﬁrst-episode patients using seven seed regions de-
ﬁned as areas in which patients showed abnormalities in regional am-
plitudes of low frequency ﬂuctuations (ALFF), a different measure of
spontaneous synchronous neuronal activity. They report the impact ofantipsychotics to be rather non-speciﬁc, restoring connectivity patterns
in some areas but also affecting connectivity to areas that were not al-
tered before treatment (Lui et al., 2010b). Our group recently examined
the effects of risperidone on resting state connectivity patterns of ven-
tral tegmental area (VTA), the origin of mesocorticolimbic dopamine
projections and reported that risperidone partially attenuates VTA
dysconnectivity after one week of treatment. Interestingly, we had
found that connectivity between the VTA andDMN aswell as the dorsal
anterior cingulate cortex at baseline, while unmedicated, correlated
with eventual clinical response to medication (Hadley et al., 2014).
Now, we again report a relationship between functional connectivity
(in this case the DAN) in unmedicated patients and eventual clinical re-
sponse to antipsychotic medication. In a recent seed-based resting state
study with a similar clinical design to ours, Sarpal and colleagues have
examined longitudinal effects of treatment with second generation an-
tipsychotic medications (risperidone and aripiprazole) on striatum
functional connectivity in patients with ﬁrst episode psychosis and re-
port a cortico-striatal connectivity increase as a function of clinical
symptom improvement (Sarpal et al., 2015). Contrasting to our study,
the authors did not ﬁnd differences in connectivity at baseline between
patients and healthy controls, whichmay due to not all of their subjects
having an antipsychotic free interval prior to the baseline scan.
Our ﬁnding of attenuation in DAN hyperconnectivity with medica-
tion is consistent with recent drug challenge studies demonstrating
that dopamine antagonism may reduce connectivity in task positive
networks (Cole et al., 2013a). The DAN controls goal-oriented, top-
down deployment of attention. In medication-naïve patients with
schizophrenia, reduced activation of the DAN during an antisaccade
task has been reported to be partially restored by risperidone (Keedy
et al., 2015). One may speculate that the extent of increased functional
connectivity in the DANmay reﬂect the system's ability to maintain in-
tegrated (mal)adaptive functional systems and neuroplasticity, and
thus be related to better treatment response (Gerretsen et al., 2014).
Though it remains unclear how antipsychotic drugsmodulate function-
al connectivity, several mechanisms have been proposed. Antipsychotic
medications principally act via blockage of the dopamine D2 receptor.
However, it is unlikely that observed changes were due solely to chang-
es in dopaminergic transmission, given the indirect nature of the BOLD
response in relation to neuronal activity (Logothetis and Wandell,
2004). Evidence from both cross-sectional and longitudinal studies sug-
gests that abnormally elevated glutamate levels may decrease with an-
tipsychotic treatment, potentially attenuating excitation/inhibition
imbalances and restoring functional connectivity (Kraguljac et al.,
2012; Kraguljac et al., 2013; de la Fuente-Sandoval et al., 2013; Kegeles
et al., 2012). Work in animal models suggests that antipsychotics may
have effects on white matter volumes, myelination, and numbers of ol-
igodendrocytes (Bartzokis et al., 2009; Dorph-Petersen et al., 2005;
Konopaske et al., 2008). Consistent with this, diffusion tensor imaging
(DTI) studies in ﬁrst episode schizophrenia report a decrease in frac-
tional anisotropy (FA), a marker of white matter structural integrity,
after twelve weeks of treatment with antipsychotic medication
(Szeszko et al., 2014). It is possible that some of the changes in function-
al networks seen with treatment are secondary to antipsychotic in-
duced changes in underlying structural networks.
Of course, our results have to be interpreted in context of several
limitations. Resting state functional MRI is prone to contamination by
head motion and non-neuronal signals such as heart beat. To minimize
the chance of spurious correlations, we usedwell-validated preprocess-
ing techniques and motion “scrubbing”. Medication compliance was
monitored with pill counts at each visit, but we did not have serum ris-
peridone levels available to conﬁrm adherence. Also, because known ef-
fective treatments cannot be withheld, we did not have a placebo group
in this study, rendering it impossible to deﬁnitively attribute DAN con-
nectivity changes over six weeks in the SZ group to medication effects
rather than time, or lack of stability/reliability in functional connectivity
measures. However, given that we did not ﬁnd signiﬁcant functional
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apart and that within network test-retest reliability was fair to high
(Wang et al., 2013), it is likely that changes seen in patients are due to
effects of treatment. Our SZ group included ﬁve subjects who were
chronically ill, but had no prior exposure to antipsychotic treatment. Be-
cause of the limited number of subjects, we were unable to examine
connectivity patterns in this subgroup, but it will be important for future
studies to determine if patients with an extended duration of untreated
psychosis are more similar to medication-naïve subjects with shorter
illness duration or to chronically ill patients with prior exposure to anti-
psychotics. An unresolved issue in the literature lays in accounting for
multiple comparisons when using several seed regions. We attempted
to mitigate this by limiting comparisons to voxels that were recruited
by their respective networks, substantially reducing the likelihood of
type I errors. However, future studies are warranted to investigate the
replicability of our ﬁndings.
In summary, our results demonstrate abnormalities in large scale
functional networks in patients with schizophrenia that are modulated
by risperidone only to a certain extent, highlighting the need for devel-
opment of novel antipsychotic medications that have the ability to alle-
viate symptoms through attenuation of dysconnectivity. Given the
considerable overlap in clinical presentation and management across
the spectrum of psychotic disorders, it would be important for future
studies to examine if antipsychotic medication effects on connectivity
are speciﬁc to schizophrenia or extend to other diagnostic constructs.
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